
Validea's guru fundamental report indicates Gilead Sciences (GILD), a large-cap biotechnology stock, scores 75% on Meb Faber's Shareholder Yield Investor model, falling below the 80% threshold for 'some interest'. Notably, GILD failed the critical 'Net Payout Yield' and 'Shareholder Yield' tests within this cash-return-focused strategy, despite passing on valuation, quality/debt, and relative strength.
According to a Validea fundamental report, Gilead Sciences, Inc. (GILD) exhibits a mixed profile under Meb Faber's Shareholder Yield Investor model. The company, a large-cap growth stock in the biotechnology sector, achieved a score of 75%, which falls below the 80% threshold that typically signifies initial interest for this specific strategy. While GILD passed tests related to its valuation, quality and debt structure, and relative strength, it critically failed on the core criteria of 'Net Payout Yield' and 'Shareholder Yield'. This indicates that despite other fundamental strengths, the company's current efforts in returning cash to shareholders through dividends, buybacks, and debt reduction are not robust enough to meet the high standards of this particular quantitative screen. The overall neutral sentiment score of 0.0 reflects this dichotomy, suggesting the positive factors are offset by the primary weakness in cash returns.
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request a DemoOverall Sentiment
mixed
Sentiment Score
0.00
Ticker Sentiment